Sub-analysis of the START-ANTIPLATELET registry [4] confirms that clopidogrel, rather than potent P2Y12 inhibitors, is frequently used in real-world practice, especially in acute coronary syndrome patients with high ischemic and bleeding risk. This evidence concerns the gene P2RY12 and acute coronary syndrome.